TABLE 8.
Treatment Differences: Pain (Healthy Subjects)
| Variable | Comparison | Difference* | Two-sided 90% CI (P value) |
|---|---|---|---|
| Maximum pain† (mm) | IgPro16 (15 mL) – Vivaglobin® IgPro20 (15 mL) – Vivaglobin® IgPro20 (12 mL) – Vivaglobin® |
−2.54 −1.64 −2.43 |
−4.82, −0.26 (P=.0679) −3.92, 0.64 (P=.2340) −4.71, −0.15 (P=.0801) |
| Mean pain† (mm) | IgPro16 (15 mL) – Vivaglobin® IgPro20 (15 mL) – Vivaglobin® IgPro20 (12 mL) – Vivaglobin® |
−1.41 −0.94 −1.54 |
−2.50, −0.33 (P=.0328) −2.02, 0.15 (P=.1545) −2.62, −0.46 (P=.0205) |
A negative difference indicates a generally higher value of maximum/mean pain under Vivaglobin®.
Pain was assessed by subjects on a 100-mm VAS; numbers given are from that scale.
Source: Adapted from Hagan 2010.